SI2625199T1 - Procedures for treating psoriasis using IL-17 antagonists - Google Patents
Procedures for treating psoriasis using IL-17 antagonists Download PDFInfo
- Publication number
- SI2625199T1 SI2625199T1 SI201131408T SI201131408T SI2625199T1 SI 2625199 T1 SI2625199 T1 SI 2625199T1 SI 201131408 T SI201131408 T SI 201131408T SI 201131408 T SI201131408 T SI 201131408T SI 2625199 T1 SI2625199 T1 SI 2625199T1
- Authority
- SI
- Slovenia
- Prior art keywords
- secukinumab
- patient
- psoriasis
- dose
- treatment
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract 9
- 239000005557 antagonist Substances 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims 2
- 229960004540 secukinumab Drugs 0.000 claims abstract 13
- 238000012423 maintenance Methods 0.000 claims 3
- 238000010254 subcutaneous injection Methods 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- 238000009121 systemic therapy Methods 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 1
- 102000004554 Interleukin-17 Receptors Human genes 0.000 abstract 2
- 108010017525 Interleukin-17 Receptors Proteins 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39138810P | 2010-10-08 | 2010-10-08 | |
| EP11764764.4A EP2625199B1 (en) | 2010-10-08 | 2011-10-07 | Methods of treating psoriasis using il-17 antagonists |
| PCT/EP2011/067522 WO2012045848A1 (en) | 2010-10-08 | 2011-10-07 | Methods of treating psoriasis using il-17 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2625199T1 true SI2625199T1 (en) | 2018-03-30 |
Family
ID=44759699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131408T SI2625199T1 (en) | 2010-10-08 | 2011-10-07 | Procedures for treating psoriasis using IL-17 antagonists |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US9717791B2 (enExample) |
| EP (5) | EP2625199B1 (enExample) |
| JP (2) | JP5537740B2 (enExample) |
| KR (3) | KR20130110179A (enExample) |
| CN (2) | CN107029234A (enExample) |
| AU (1) | AU2011311482B2 (enExample) |
| BR (1) | BR112013008501A2 (enExample) |
| CA (1) | CA2813900C (enExample) |
| CL (1) | CL2013000930A1 (enExample) |
| CY (1) | CY1119942T1 (enExample) |
| DK (1) | DK2625199T3 (enExample) |
| ES (1) | ES2660770T3 (enExample) |
| HK (1) | HK1247932A1 (enExample) |
| HR (1) | HRP20180301T1 (enExample) |
| HU (1) | HUE038334T2 (enExample) |
| IL (1) | IL225310A (enExample) |
| LT (1) | LT2625199T (enExample) |
| MA (1) | MA34646B1 (enExample) |
| MX (1) | MX356279B (enExample) |
| NO (1) | NO2625199T3 (enExample) |
| PH (1) | PH12013500660B1 (enExample) |
| PL (1) | PL2625199T3 (enExample) |
| PT (1) | PT2625199T (enExample) |
| RU (2) | RU2591083C2 (enExample) |
| SG (1) | SG188979A1 (enExample) |
| SI (1) | SI2625199T1 (enExample) |
| TW (2) | TWI548419B (enExample) |
| WO (1) | WO2012045848A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| EA201891433A3 (ru) | 2010-01-15 | 2019-02-28 | Кирин-Эмджен, Инк. | Состав антитела и терапевтические режимы |
| EP2571901B1 (en) | 2010-05-20 | 2019-01-02 | Ablynx N.V. | Biological materials related to her3 |
| KR20180129991A (ko) | 2010-11-05 | 2018-12-05 | 노파르티스 아게 | Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| KR20140097178A (ko) * | 2011-11-21 | 2014-08-06 | 노파르티스 아게 | IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법 |
| KR20150128858A (ko) * | 2013-03-15 | 2015-11-18 | 암젠 인크 | 항-il-23 항체를 사용한 건선의 치료 방법 |
| EP3693007A1 (en) * | 2013-03-15 | 2020-08-12 | Amgen, Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| WO2015022656A1 (en) | 2013-08-15 | 2015-02-19 | Novartis Ag | Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists |
| EP3088000A4 (en) | 2013-12-27 | 2017-08-09 | Osaka University | Vaccine targeting il-17a |
| RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| US20170174772A1 (en) * | 2014-03-31 | 2017-06-22 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
| WO2015176031A2 (en) | 2014-05-15 | 2015-11-19 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US11548940B2 (en) * | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| WO2016031250A1 (en) * | 2014-08-26 | 2016-03-03 | Kirin-Amgen, Inc. | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
| SI3191120T1 (sl) * | 2014-09-10 | 2024-10-30 | Novartis Ag | Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AU2016226415B2 (en) | 2015-03-02 | 2021-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using a TNF receptor 2 antagonist |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| US11492396B2 (en) * | 2015-10-27 | 2022-11-08 | UCB Biopharma SRL | Methods of treatment using anti-IL-17A/F antibodies |
| JP2019521156A (ja) | 2016-07-19 | 2019-07-25 | ノバルティス アーゲー | Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2019505516A (ja) * | 2016-11-28 | 2019-02-28 | ノバルティス アーゲー | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 |
| WO2018158741A1 (en) * | 2017-03-03 | 2018-09-07 | Novartis Ag | Psoriasis disease modification following long-term treatment with an il-17 antagonist |
| WO2019040230A1 (en) * | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | TREATMENT OF GENITAL PSORIASIS |
| TWI725532B (zh) * | 2018-09-11 | 2021-04-21 | 美商美國禮來大藥廠 | 治療牛皮癬之方法 |
| CN114127108A (zh) | 2019-07-30 | 2022-03-01 | 江苏恒瑞医药股份有限公司 | Il-17拮抗剂治疗自身免疫疾病的方法 |
| CN114981302A (zh) | 2019-09-20 | 2022-08-30 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法 |
| WO2022127842A1 (zh) * | 2020-12-17 | 2022-06-23 | 上海华奥泰生物药业股份有限公司 | 靶向il-17a和il-36r的双特异性抗体及其应用 |
| TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| WO2023186174A1 (en) * | 2022-04-01 | 2023-10-05 | Zai Lab (Shanghai) Co., Ltd. | Topical formulation comprising an il-17a binding molecule and uses thereof |
| CN116593718B (zh) * | 2023-07-18 | 2023-09-15 | 军科正源（北京）药物研究有限责任公司 | 用于检测司库奇尤单抗抗药性抗体的试剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9422306D0 (en) * | 1994-11-04 | 1994-12-21 | Sandoz Ltd | Organic compounds |
| US6093745A (en) * | 1997-11-25 | 2000-07-25 | Psorx, L.L.C. | Methods and composition for treating skin proliferative diseases |
| AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| WO2007027761A2 (en) * | 2005-09-01 | 2007-03-08 | Schering Corporation | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
| CN101326195B9 (zh) * | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| RU2367429C2 (ru) | 2007-01-30 | 2009-09-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Способ лечения псориаза |
| EP2152318A4 (en) * | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| RU2341272C1 (ru) * | 2007-10-22 | 2008-12-20 | Левон Никитович Мкртчян | Средство для неспецифической иммунотерапии |
| BRPI0919531A2 (pt) * | 2008-09-29 | 2015-12-08 | Roche Glycart Ag | anticorpos contra il17 humana e usos dos mesmos |
-
2011
- 2011-10-07 WO PCT/EP2011/067522 patent/WO2012045848A1/en not_active Ceased
- 2011-10-07 EP EP11764764.4A patent/EP2625199B1/en active Active
- 2011-10-07 DK DK11764764.4T patent/DK2625199T3/en active
- 2011-10-07 TW TW100136608A patent/TWI548419B/zh active
- 2011-10-07 PL PL11764764T patent/PL2625199T3/pl unknown
- 2011-10-07 BR BR112013008501A patent/BR112013008501A2/pt active Search and Examination
- 2011-10-07 PH PH1/2013/500660A patent/PH12013500660B1/en unknown
- 2011-10-07 HR HRP20180301TT patent/HRP20180301T1/hr unknown
- 2011-10-07 KR KR1020137011792A patent/KR20130110179A/ko not_active Ceased
- 2011-10-07 CA CA2813900A patent/CA2813900C/en active Active
- 2011-10-07 RU RU2013120957/15A patent/RU2591083C2/ru active
- 2011-10-07 ES ES11764764.4T patent/ES2660770T3/es active Active
- 2011-10-07 CN CN201710261381.2A patent/CN107029234A/zh active Pending
- 2011-10-07 EP EP17195148.6A patent/EP3299390A1/en not_active Withdrawn
- 2011-10-07 KR KR1020147018691A patent/KR101620771B1/ko active Active
- 2011-10-07 SI SI201131408T patent/SI2625199T1/en unknown
- 2011-10-07 RU RU2016120615A patent/RU2665954C1/ru active
- 2011-10-07 EP EP20187002.9A patent/EP3792281A1/en not_active Ceased
- 2011-10-07 KR KR1020147036815A patent/KR20150018595A/ko not_active Withdrawn
- 2011-10-07 EP EP25216056.9A patent/EP4670788A2/en active Pending
- 2011-10-07 NO NO11764764A patent/NO2625199T3/no unknown
- 2011-10-07 MX MX2013003916A patent/MX356279B/es active IP Right Grant
- 2011-10-07 US US13/876,367 patent/US9717791B2/en active Active
- 2011-10-07 HU HUE11764764A patent/HUE038334T2/hu unknown
- 2011-10-07 PT PT117647644T patent/PT2625199T/pt unknown
- 2011-10-07 AU AU2011311482A patent/AU2011311482B2/en active Active
- 2011-10-07 SG SG2013018486A patent/SG188979A1/en unknown
- 2011-10-07 LT LTEP11764764.4T patent/LT2625199T/lt unknown
- 2011-10-07 TW TW105116323A patent/TWI564022B/zh active
- 2011-10-07 JP JP2013532213A patent/JP5537740B2/ja active Active
- 2011-10-07 EP EP22186296.4A patent/EP4137514A1/en active Pending
- 2011-10-07 CN CN2011800487322A patent/CN103154031A/zh active Pending
-
2013
- 2013-03-18 IL IL225310A patent/IL225310A/en active IP Right Grant
- 2013-04-05 CL CL2013000930A patent/CL2013000930A1/es unknown
- 2013-05-03 MA MA35872A patent/MA34646B1/fr unknown
- 2013-12-09 JP JP2013253745A patent/JP2014114288A/ja not_active Withdrawn
-
2017
- 2017-06-22 US US15/630,577 patent/US10583190B2/en active Active
-
2018
- 2018-02-22 CY CY20181100220T patent/CY1119942T1/el unknown
- 2018-06-01 HK HK18107225.2A patent/HK1247932A1/en unknown
-
2019
- 2019-12-19 US US16/720,351 patent/US11534490B2/en active Active
-
2020
- 2020-12-18 US US17/127,738 patent/US20210113688A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,724 patent/US20210162044A1/en not_active Abandoned
-
2022
- 2022-12-02 US US18/061,227 patent/US20230321231A1/en active Pending
-
2024
- 2024-12-16 US US18/983,037 patent/US20250161445A1/en active Pending
- 2024-12-16 US US18/983,030 patent/US20250161443A1/en active Pending
- 2024-12-16 US US18/983,034 patent/US20250161444A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| JP2015007098A5 (enExample) | ||
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| EA201200002A1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
| FI3757126T3 (fi) | Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla | |
| RU2013108248A (ru) | Иммуногенные противовоспалительные композиции | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| EA201691251A1 (ru) | Цитотоксические пептиды и их конъюгаты | |
| JP2016530280A5 (enExample) | ||
| BR112015010396A2 (pt) | terapia de combinação | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| JP2015525798A5 (enExample) | ||
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| EP3309555A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
| HRP20200019T1 (hr) | Terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| TW201129361A (en) | Methods for treating pain | |
| MX2020005438A (es) | Formas de dosificacion de sulfato de morfina disuasivas del abuso. |